## **UPDATED FEASIBILITY WITH CLINICAL DATA**
### **TIER 1 TARGETS - IMMEDIATE COMMERCIAL VIABILITY**
#### **1. NAD+ Salvage Pathway (NAMPT/CD38) - HIGHEST PRIORITY**
**Clinical Validation:**
- **NCT04430517**: McLean Hospital studying NR in MCI/mild AD (n=50, active)
- **NCT05617508**: Completed Phase 2 dose optimization (n=80, up to 3g daily)
- **NCT05040321**: Brigham & Women's testing MIB-626 BBB penetration
- **NCT07278492**: MIB-626 in Down syndrome (Alzheimer's model)
**Competitive Landscape:**
- **ChromaDex Corp**: NIAGEN® (NR supplement) - $100M+ revenue
- **Elysium Health**: BASIS (NAD+ precursors) - consumer market
- **Metro International Biotech**: Clinical-grade NMN development
- **MetroBiotech**: Advanced NAD+ therapeutics
**Investment Thesis:**
- Strong clinical precedent with 4+ active trials
- Proven CNS penetration (MIB-626 data)
- Multiple chemical approaches (NR, NMN, activators)
- **Immediate opportunity**: Partner with existing players or develop next-gen formulations
**Timeline/Investment:** 4-7 years, $200-500M (fast-follower strategy)
#### **2. mTOR Pathway Repurposing - STRONG SECOND**
**Clinical Validation:**
- **NCT04629495**: UT San Antonio Phase 2 rapamycin in MCI/AD (n=40, recruiting)
- **NCT04200911**: Completed proof-of-concept CNS penetration study
- **NCT06022068**: Karolinska Institute PET imaging study completed
**Competitive Assessment:**
- **University of Texas**: Leading academic effort (rapamycin repurposing)
- **Karolinska Institute**: European clinical development
- **No major pharma investment yet** - opportunity exists
**Investment Thesis:**
- FDA-approved drug (de-risked safety profile)
- Proven CNS activity in ongoing trials
- Repurposing advantage reduces development costs
- **Market gap**: No major pharma player committed
**Timeline/Investment:** 5-8 years, $300-600M (repurposing advantage)
### **TIER 2 TARGETS - MEDIUM-TERM OPPORTUNITIES**
#### **3. P2Y12 Modulation - UNDEREXPLORED CNS APPLICATION**
**Clinical Reality Check:**
- **NCT06714526**: Only CNS-related trial (stroke prevention, not AD)
- **No AD-specific P2Y12 trials identified**
- Clopidogrel has extensive cardiovascular safety data
**Competitive Gap:**
- Virgin territory for neurodegeneration
- Established safety profile from cardiology use
- **Need**: CNS-penetrant positive allosteric modulators
**Investment Thesis:**
- Large unmet medical need
- Proven target class with known pharmacology
- Requires novel chemistry for CNS application
- **Risk**: Bleeding safety concerns may limit dosing
**Timeline/Investment:** 8-12 years, $800M-1.2B (novel chemistry required)
### **TIER 3 TARGETS - HIGH RISK/HIGH REWARD**
The remaining targets (lipid droplets, mitochondrial contacts, lactate shuttle, sphingolipids) show limited clinical precedent and significant technical challenges.
## **FINAL INVESTMENT RECOMMENDATIONS**
### **IMMEDIATE ACTION (6-24 months):**
1. **License/acquire NAD+ assets** from ChromaDex, Elysium, or MetroBiotech
2. **Initiate academic collaboration** with UT San Antonio (mTOR) or McLean Hospital (NAD+)
3. **Conduct market analysis** of APOE4-stratified patient populations
### **MEDIUM-TERM DEVELOPMENT (2-5 years):**
1. **NAD+ Enhancement**: Develop APOE4-specific formulations or delivery systems
2. **mTOR Modulation**: Create CNS-optimized rapalogs or intermittent dosing protocols
3. **P2Y12 PAMs**: Initiate medicinal chemistry for brain-penetrant modulators
### **PARTNERSHIP OPPORTUNITIES:**
- **ChromaDex**: NAD+ precursor expertise and market presence
- **University of Texas**: mTOR repurposing clinical leadership
- **Alector**: Microglial biology and TREM2 expertise
- **Denali Therapeutics**: CNS delivery platform technologies
**Bottom Line**: NAD+ salvage pathway offers the fastest path to clinic with existing clinical validation, while mTOR repurposing provides a strong risk-adjusted opportunity. The other hypotheses require substantial additional validation before warranting significant investment.